Market Overview

Kala Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference

Share:

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company
focused on the development and commercialization of therapeutics using
its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery
Technology, today announced that it will present at the 37th
Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Mark
Iwicki, Chairman, President and Chief Executive Officer of Kala
Pharmaceuticals, is scheduled to present a corporate overview on Monday,
January 7th, 2019 at 10:30 a.m. PT (1:30 p.m. ET).

To access a live webcast and subsequent archived recording of the
presentation, please visit the "Investors & Media" section on the Kala
website at http://kalarx.com

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the development and
commercialization of therapeutics using its proprietary AMPPLIFYTM
mucus-penetrating particle (MPP) Drug Delivery Technology, with an
initial focus on the treatment of eye diseases. Kala has applied the
AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol
etabonate (LE), designed for ocular applications, resulting in recently
approved INVELTYSTM for the treatment of inflammation and
pain following ocular surgery and its lead product candidate, KPI-121
0.25%, for the temporary relief of the signs and symptoms of dry eye
disease, for which a New Drug Application (NDA) has been filed with the
United States Food and Drug Administration (FDA) and a target action
date under the Prescription Drug User Fee Act (PDUFA) has been set for
August 15, 2019.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com